Arrowhead Pharmaceuticals Presents New Pivotal Phase 3 Data at ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome
- Plozasiran reduced triglycerides by 80% from baseline and reduced the risk…
Synapticure Partners with Pearl Health to Provide Personalized Care to Medicare Patients
SynapticurePearl Health, a telehealth company serving people with neurodegenerative diseases and their…
